

PRESSRELEASE Lund, January 10, 2025

## Invitation to monthly digital events and presentations of quarterly reports

Hamlet BioPharma is pleased to announce the continuation of the digital event series in the spring of 2025. These events provide participants a valuable opportunity to follow and discuss our drug development process and engage directly with our team during the Q&A sessions that will follow each presentation. Please visit our web to join the digital events: <u>https://hamletbiopharma.com/series-of-digital-events</u>

The digital events are scheduled for:

- January 22, 2025, 12:00 CET
- March 12, 2025, 12:00 CET
- April 23, 2025, 12:00 CET
- June 18, 2025, 12:00 CET

Additionally, please note the following dates for quarterly reports this spring:

- February 13, 2025: Interim report (Q2) 2024/2025
- May 22, 2025: Interim Report (Q3) 2024/2025

Please visit our updated website at: <a href="https://hamletbiopharma.com">https://hamletbiopharma.com</a>

To receive information from the company, please subscribe at <a href="https://hamletbiopharma.com/subscribe/">https://hamletbiopharma.com/subscribe/</a>

## For more information please contact:

**Martin Erixon,** CEO, Hamlet BioPharma AB, +46 733 00 43 77 martin.erixon@hamletpharma.com

**Catharina Svanborg,** Chairman of the board, Hamlet BioPharma AB, +46 709 42 65 49, catharina.svanborg@hamletpharma.com